The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression to Type 2 diabetes in prediabetic patients, the Indianapolis-based drug | In the three-year SURMOUNT-1 trial,

Obesity is a chronic condition and a key risk factor for a range of other health issues, including type 2 diabetes. In a previous analysis of the SURMOUNT-1 trial, tirzepatide pro

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type 2 diabetes (T2D) who were either obese or overweight with complications such as cardiovascular disease, dyslipidaemia, hypertension, obstructive or sleep apnoea (OSA).

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections.

Nearly 99% of people with prediabetes and obesity or overweight who took weekly tirzepatide injections remained diabetes-free for over three years of using the drug, according to new data from the drugmaker Eli Lilly.